<DOC>
	<DOC>NCT00509990</DOC>
	<brief_summary>An open-label, multicenter study, of long term management to evaluate effectiveness, tolerability and safety of pimecrolimus cream 1% in pediatric patients with mild to moderate atopic dermatitis in a daily practice</brief_summary>
	<brief_title>Open Label Study of Long Term Treatment of Pediatric Treatment of Atopic Dermatitis With Pimecrolimus Cream 1% Within a Usual Clinical Setting</brief_title>
	<detailed_description />
	<mesh_term>Dermatitis</mesh_term>
	<mesh_term>Dermatitis, Atopic</mesh_term>
	<mesh_term>Eczema</mesh_term>
	<mesh_term>Pimecrolimus</mesh_term>
	<mesh_term>Tacrolimus</mesh_term>
	<criteria>Age ≥ 3 months to 12 years old Clinical diagnosis of atopic dermatitis History of mild to moderate atopic dermatitis Investigator Global Assessment ≥ 1 (almost clear/clear of disease) Written informed consent Investigator Global Assessment ≥ 4 (severe/very severe disease) Patients with active skin viral infections (i.e, herpes simplex, herpes zoster, varicella) Patients with atopic dermatitis, with active clinical infection on area of disease. All active infections must be treated prior to trial inclusion Patients in an Immunosuppressive state or with history of malignant disease Patients with clinical conditions other that Atopic Dermatitis that according to the investigator may interfere with the evaluation (i.e, Psoriasis, Netherton Syndrome) Other protocoldefined inclusion/exclusion criteria may apply</criteria>
	<gender>All</gender>
	<minimum_age>3 Months</minimum_age>
	<maximum_age>12 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Atopic dermatitis, pimecrolimus, children</keyword>
</DOC>